Search Results - "Jensen, PEH"

Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study by Leurs, CE, Twaalfhoven, HAM, Lissenberg-Witte, BI, van Pesch, V, Dujmovic, I, Drulovic, J, Castellazzi, M, Bellini, T, Pugliatti, M, Kuhle, J, Villar, LM, Alvarez-Cermeño, JC, Alvarez-Lafuente, R, Hegen, H, Deisenhammer, F, Walchhofer, LM, Thouvenot, E, Comabella, M, Montalban, X, Vécsei, L, Rajda, C, Galimberti, D, Scarpini, E, Altintas, A, Rejdak, K, Frederiksen, JL, Pihl-Jensen, G, Jensen, PEH, Khalil, M, Voortman, MM, Fazekas, F, Saiz, A, La Puma, D, Vercammen, M, Vanopdenbosch, L, Uitdehaag, BMJ, Killestein, J, Bridel, C, Teunissen, C

“…Objective: To validate kappa free light chain (KFLC) and lambda free light chain (LFLC) indices as a diagnostic biomarker in multiple sclerosis (MS). Methods:…”
Get full text

Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis by van der Weele, Linda, Pollastro, Sabrina, van Schaik, Barbera D.C., van Kampen, Antoine H.C., Niewold, Ilse T.G., Kuijpers, Taco W., Warnke, Clemens, Jensen, Poul Erik H., Kramer, Daniel, Ryner, Malin, Hermanrud, Christina, Dönnes, Pierre, Pallardy, Marc, Spindeldreher, Sebastian, Deisenhammer, Florian, Fogdell-Hahn, Anna, de Vries, Niek

“…A significant proportion of multiple sclerosis (MS) patients treated with interferon beta-1a (Rebif™) develop anti-drug antibodies (ADA) with a negative impact…”
Get full text

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium by Rup, B., Pallardy, M., Sikkema, D., Albert, T., Allez, M., Broet, P., Carini, C., Creeke, P., Davidson, J., De Vries, N., Finco, D., Fogdell‐Hahn, A., Havrdova, E., Hincelin‐Mery, A., C. Holland, M., H. Jensen, P. E., Jury, E. C., Kirby, H., Kramer, D., Lacroix‐Desmazes, S., Legrand, J., Maggi, E., Maillère, B., Mariette, X., Mauri, C., Mikol, V., Mulleman, D., Oldenburg, J., Paintaud, G., R. Pedersen, C., Ruperto, N., Seitz, R., Spindeldreher, S., Deisenhammer, F.

“…Summary Biopharmaceuticals (BPs) represent a rapidly growing class of approved and investigational drug therapies that is contributing significantly to…”
Get full text

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort by Olsson, Tomas, Achiron, Anat, Alfredsson, Lars, Berger, Thomas, Brassat, David, Chan, Andrew, Comi, Giancarlo, Eraksoy, Mefkure, Hegen, Harald, Hillert, Jan, Jensen, Poul Erik Hyldgaard, Moiola, Lucia, Myhr, Kjell-Morten, Oturai, Annette, Schippling, Sven, Siva, Aksel, Sorensen, Per Soelberg, Trampe, Anne-Kathrin, Weber, Thomas, Potts, James, Plavina, Tatiana, Paes, Dominic, Subramanyam, Meena, Wiendl, Heinz, Dib, Hussein, Üren, Deniz, Hemmer, Bernhard, Buck, Dorothea

“…JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large,…”
Get full text

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results by Link, Jenny, Ramanujam, Ryan, Auer, Michael, Ryner, Malin, Hässler, Signe, Bachelet, Delphine, Mbogning, Cyprien, Warnke, Clemens, Buck, Dorothea, Hyldgaard Jensen, Poul Erik, Sievers, Claudia, Ingenhoven, Kathleen, Fissolo, Nicolas, Lindberg, Raija, Grummel, Verena, Donnellan, Naoimh, Comabella, Manuel, Montalban, Xavier, Kieseier, Bernd, Soelberg Sørensen, Per, Hartung, Hans-Peter, Derfuss, Tobias, Lawton, Andy, Sikkema, Dan, Pallardy, Marc, Hemmer, Bernhard, Deisenhammer, Florian, Broët, Philippe, Dönnes, Pierre, Davidson, Julie, Fogdell-Hahn, Anna

“…Antibodies against biopharmaceuticals (anti-drug antibodies, ADA) have been a well-integrated part of the clinical care of multiple sclerosis (MS) in several…”
Get full text

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis by Bachelet, Delphine, Hässler, Signe, Mbogning, Cyprien, Link, Jenny, Ryner, Malin, Ramanujam, Ryan, Auer, Michael, Hyldgaard Jensen, Poul Erik, Koch-Henriksen, Nils, Warnke, Clemens, Ingenhoven, Kathleen, Buck, Dorothea, Grummel, Verena, Lawton, Andy, Donnellan, Naoimh, Hincelin-Mery, Agnès, Sikkema, Dan, Pallardy, Marc, Kieseier, Bernd, Hemmer, Bernard, Hartung, Hans Peter, Soelberg Sorensen, Per, Deisenhammer, Florian, Dönnes, Pierre, Davidson, Julie, Fogdell-Hahn, Anna, Broët, Philippe

“…Immunogenicity of biopharmaceutical products in multiple sclerosis is a frequent side effect which has a multifactorial etiology. Here we study associations…”
Get full text

Late-onset myasthenia not on the increase: a nationwide register study in Denmark, 1996-2009 by Pedersen, E. G., Hallas, J., Hansen, K., Jensen, P. E. H., Gaist, D.

“…Background An increase in late‐onset myasthenia gravis (MG) has been reported. There are few large population‐based studies over longer periods of time…”
Get full text

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS by Andlauer, Till F M, Link, Jenny, Martin, Dorothea, Ryner, Malin, Hermanrud, Christina, Grummel, Verena, Auer, Michael, Hegen, Harald, Aly, Lilian, Gasperi, Christiane, Knier, Benjamin, Müller-Myhsok, Bertram, Jensen, Poul Erik Hyldgaard, Sellebjerg, Finn, Kockum, Ingrid, Olsson, Tomas, Pallardy, Marc, Spindeldreher, Sebastian, Deisenhammer, Florian, Fogdell-Hahn, Anna, Hemmer, Bernhard

“…Upon treatment with biopharmaceuticals, the immune system may produce anti-drug antibodies (ADA) that inhibit the therapy. Up to 40% of multiple sclerosis…”
Get full text

Genetic variants are major determinants of CSF antibody levels in multiple sclerosis by Goris, An, Pauwels, Ine, Gustavsen, Marte W, van Son, Brechtje, Hilven, Kelly, Bos, Steffan D, Celius, Elisabeth Gulowsen, Berg-Hansen, Pål, Aarseth, Jan, Myhr, Kjell-Morten, D'Alfonso, Sandra, Barizzone, Nadia, Leone, Maurizio A, Martinelli Boneschi, Filippo, Sorosina, Melissa, Liberatore, Giuseppe, Kockum, Ingrid, Olsson, Tomas, Hillert, Jan, Alfredsson, Lars, Bedri, Sahl Khalid, Hemmer, Bernhard, Buck, Dorothea, Berthele, Achim, Knier, Benjamin, Biberacher, Viola, van Pesch, Vincent, Sindic, Christian, Bang Oturai, Annette, Søndergaard, Helle Bach, Sellebjerg, Finn, Jensen, Poul Erik H, Comabella, Manuel, Montalban, Xavier, Pérez-Boza, Jennifer, Malhotra, Sunny, Lechner-Scott, Jeannette, Broadley, Simon, Slee, Mark, Taylor, Bruce, Kermode, Allan G, Gourraud, Pierre-Antoine, Sawcer, Stephen J, Andreassen, Bettina Kullle, Dubois, Bénédicte, Harbo, Hanne F

“…Immunological hallmarks of multiple sclerosis include the production of antibodies in the central nervous system, expressed as presence of oligoclonal bands…”
Get full text

Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study by Jensen, Poul Erik H., Warnke, Clemens, Ingenhoven, Kathleen, Piccoli, Luca, Gasis, Marcia, Hermanrud, Christina, Fernandez-Rodriguez, Blanca M., Ryner, Malin, Kramer, Daniel, Link, Jenny, Ramanujam, Ryan, Auer, Michael, Buck, Dorothea, Grummel, Verena, Bertotti, Elisa, Fissolo, Nicolas, Oliver-Martos, Begoña, Nytrova, Petra, Khalil, Michael, Guger, Michael, Rathmaier, Sandra, Sievers-Stober, Claudia, Lindberg, Raija L.P., Hässler, Signe, Bachelet, Delphine, Aktas, Orhan, Donnellan, Naoimh, Lawton, Andy, Hemmer, Bernhard, Havrdova, Eva Kubala, Kieseier, Bernd, Hartung, Hans-Peter, Comabella, Manuel, Montalban, Xavier, Derfuss, Tobias, Sellebjerg, Finn, Dönnes, Pierre, Pallardy, Marc, Spindeldreher, Sebastian, Broët, Philippe, Deisenhammer, Florian, Fogdell-Hahn, Anna, Sorensen, Per Soelberg

“…Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta…”
Get full text

Short report: Real-life analysis of the occurrence of persistent, transient, and fluctuating positive titres of neutralizing anti-drug antibodies in multiple sclerosis patients treated with interferon beta by Oviedo Querejazu, Matilde, Dunn, Nicky, Ramanujam, Ryan, Ryner, Malin, Auer, Michael, Hyldgaard Jensen, Poul Erik, Deisenhammer, Florian, Fogdell-Hahn, Anna

“…•Transient and fluctuating patterns of NAbs against interferon-β in MS are rare.•Patients with transient patterns of NAbs generally present with low titres.•In…”
Get full text

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study by Oturai, A. B., Koch-Henriksen, N., Petersen, T., Jensen, P. E. H., Sellebjerg, F., Sorensen, P. S.

“…Introduction:  Previous studies of natalizumab (Tysabri®) in relapsing multiple sclerosis (MS) patients have included patients with moderate disease activity…”
Get full text

Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles by Mero, Inger-Lise, Gustavsen, Marte W, Sæther, Hanne S, Flåm, Siri T, Berg-Hansen, Pål, Søndergaard, Helle B, Jensen, Poul Erik H, Berge, Tone, Bjølgerud, Anja, Muggerud, Aslaug, Aarseth, Jan H, Myhr, Kjell-Morten, Celius, Elisabeth G, Sellebjerg, Finn, Hillert, Jan, Alfredsson, Lars, Olsson, Tomas, Oturai, Annette Bang, Kockum, Ingrid, Lie, Benedicte A, Andreassen, Bettina Kulle, Harbo, Hanne F

“…The presence of oligoclonal bands (OCB) in cerebrospinal fluid (CSF) is a typical finding in multiple sclerosis (MS). We applied data from Norwegian, Swedish…”
Get full text

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab by Sørensen, Per Soelberg, Hyldgaard Jensen, Poul Erik, Haghikia, Aiden, Lundkvist, Malin, Vedeler, Christian, Sellebjerg, Finn, Koch-Henriksen, Nils, Fogdell-Hahn, Anna, Myhr, Kjell-Morten, Hillert, Jan, Gold, Ralf

“…Background: In the clinical trials about 9% of natalizumab treated multiple sclerosis (MS) patients generated anti-natalizumab antibodies, of which 6% were…”
Get full text

Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark by Pedersen, E. G., Pottegård, A., Hallas, J., Friis, S., Hansen, K., Jensen, P. E. H., Gaist, D.

“…Background and purpose To evaluate the association between the use of azathioprine and risk of cancer in patients with non‐thymoma myasthenia gravis (MG) in a…”
Get full text

Myasthenia and risk of cancer: a population-based case-control study by Pedersen, E. G., Pottegård, A., Hallas, J., Friis, S., Hansen, K., Jensen, P. E. H., Gaist, D.

“…Background and purpose To evaluate the association between having non‐thymoma myasthenia and the risk of extra‐thymic cancer in a population‐based setting…”
Get full text

Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients by Jensen, P. E. H., Sellebjerg, F., Søndergaard, H. B., Sørensen, P. S.

“…Background and purpose Measurements of binding antibodies (BAbs), neutralizing antibodies (NAbs) and MX1 mRNA expression are used to analyse the immunological…”
Get full text

Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients by Adriani, Marsilio, Nytrova, Petra, Mbogning, Cyprien, Hässler, Signe, Medek, Karel, Jensen, Poul Erik H, Creeke, Paul, Warnke, Clemens, Ingenhoven, Kathleen, Hemmer, Bernhard, Sievers, Claudia, Lindberg Gasser, Raija Lp, Fissolo, Nicolas, Deisenhammer, Florian, Bocskei, Zsolt, Mikol, Vincent, Fogdell-Hahn, Anna, Kubala Havrdova, Eva, Broët, Philippe, Dönnes, Pierre, Mauri, Claudia, Jury, Elizabeth C

“…Multiple sclerosis (MS) is an autoimmune disease characterized by CNS inflammation leading to demyelination and axonal damage. IFN-β is an established…”
Get full text

Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis by Petersen, ER, Søndergaard, HB, Oturai, AB, Jensen, PEH, Sorensen, PS, Sellebjerg, F, Börnsen, L

“…Abstract Background Natalizumab reduces disease activity in multiple sclerosis (MS). Natalizumab binds to the very late antigen-4 and inhibits vascular cell…”
Get full text

Genetic factors influencing the development of binding and neutralizing antibodies against interferon beta treatment in multiple sclerosis patients by Andlauer, TFM, Link, J, Buck, D, Ryner, M, Grummel, V, Auer, M, Hegen, H, Gasperi, C, Muller-Myhsok, B, Jensen, PEH, Sellebjerg, FT, Kockum, I, Olsson, T, Pallardy, M, Spindeldreher, S, Deisenhammer, F, Fogdell-Hahn, A, Hemmer, B

Get full text